[Modalities for the functionning of a Care Center for women at high risk for breast and ovarian cancers: The French experience of Tenon Hospital].
High risk may be defined as either an absolute risk greater than 20 % or a relative risk greater than 4. Concerning breast and ovarian cancer, high risk patients include carriers of a constitutive deleterious mutation of BRCA1 or BRCA2 genes, patients with a significant family history of breast or ovarian cancer, and patients who have been diagnosed a benign breast lesion with a high risk of degeneration, i.e. atypical hyperplasia. Following up such patients relies on specific strategies. A center including a large panel of physicians involved in the various modalities for patients' management (geneticians, radiologists, gynecologists, plastic surgeons, pathologists, endocrinologists, psychologists, medical oncologists) has been created at Tenon Hospital with this purpose. The collaboration of these different specialists with the referent physician of the patient allows for the definition and the implementation of a patient-centered follow-up continuously updated to take into account the different periods of a woman's life, according to best practices recommendations and the evolving state-of-the art.
Chabbert-Buffet
N
N
Centre de suivi des femmes à haut risque de cancer du sein et de l'ovaire, service de gynécologie obstétrique et médecine de la reproduction, hôpital Tenon, AP-HP, UPMC Paris-06, 4, rue de la Chine, 75020 Paris, France.
Seroussi
B
B
Chopier
J
J
Fajac
A
A
Antoine
M
M
Boucher
C
C
Colas
C
C
Belaroussi
B
B
Waserman
C
C
Deschamps
M-O
MO
Cuminet
J
J
Mottier
N
N
Buzzi
J-C
JC
Rouzier
R
R
Soubrier
F
F
Uzan
S
S
D001940:Breast / Q000473:pathology; D001941:Breast Diseases / Q000473:pathology; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D005602:France; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D020022:Genetic Predisposition to Disease; D006757:Hospital Units / Q000458:organization & administration*; D006801:Humans; D006965:Hyperplasia; D009154:Mutation; D010051:Ovarian Neoplasms / Q000235:genetics / Q000517:prevention & control*; D010820:Physicians; D012017:Referral and Consultation; D012307:Risk Factors; D013038:Specialization